Given that cisplatin-based chemotherapy is commonly used to treat HNSCC patients, it would be of major interest to address the role and expression of ANXA9 in cisplatin resistance in these tumors. This evidence concerns the gene ANXA9 and head and neck squamous cell carcinoma.